Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

AIM: To examine the underlying mechanisms of erlotinib-induced growth inhibition in
hepatocellular carcinoma (HCC). METHODS: Erlotinib-induced alterations in gene …

Background Multidrug resistance is a major reason for poor treatment results in advanced
hepatoblastoma (HB). Several alternative treatment options are currently under investigation …

Mutations affecting the Wnt/β‑catenin pathway have been identified in 26‑40% of
hepatocellular carcinoma (HCC) cases. Aberrant activation of this pathway leads to …

Purpose To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in
patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational …

Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-
regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important …

Background Treatment outcome of children with pediatric hepatocellular carcinoma (pHCC)
is poor. Therefore, we evaluated the tyrosine kinase inhibitor sorafenib in a model of pHCC …

Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …

ABSTRACT Angiogenesis and RAS/RAF/MEK/ERK pathway have been demonstrated to be
relevant in hepatocellular carcinoma (HCC). Sorafenib, an oral multikinase inhibitor with …

Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …